{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042333","form_type":"8-K","ticker":null,"cik":"0001413754","company_name":"MARIZYME, INC.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.983655+00:00","generated_at":"2026-06-07T22:35:54.588309+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Marizyme completes fifth closing of OID unit private placement, raises $550,000 cash","bullets":["Issued $647,062 principal amount of 15% OID convertible notes convertible at $0.10 per share to six investors for $550,000 cash.","Also issued Class E warrants (8.1M shares at $0.10) and Class F warrants (8.1M shares at $0.20) to the same investors.","Cancelled $150,319 of short-term debt to three consultants by issuing $176,847 principal amount of notes and equivalent warrants.","Net cash proceeds after 8% placement agent fee to Univest Securities were $506,000; no fee on debt cancellation.","Notes mature August 20, 2024; warrants exercisable for five years; registration rights waived by all investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042333","json":"https://secwatch.observer/filing/0001493152-23-042333.json","markdown":"https://secwatch.observer/filing/0001493152-23-042333.md","text":"https://secwatch.observer/filing/0001493152-23-042333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1413754/000149315223042333/0001493152-23-042333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1413754/000149315223042333/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:35:54.588309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de6b795a132a798294bb4b44cc7cd7dc7826fa87","claim":"MARIZYME, INC. incurred convertible notes of aggregate principal amount of $647,062 with nine investors at 15% original issue discount.","evidence_excerpt":"the Company issued to these investors 6,470,620 OID Units in aggregate consisting of (i) OID Convertible Notes in the aggregate principal amount of $647,062, convertible into 6,470,620 shares of common stock plus additional shares based on accrued interest at $0.10 per share, subject to adjustment","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1413754/000149315223042333/0001493152-23-042333-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"aggregate principal amount of $647,062"},{"label":"Counterparty","value":"nine investors"},{"label":"Rate","value":"15% original issue discount"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"c1796541db666cdb210f5b8276c4d51ae7203106","claim":"MARIZYME, INC. entered into November 2023 OID Unit Purchase Agreement with each of nine investors valued at up to $10,000,000 (effective 2023-11-20).","evidence_excerpt":"On November 20, 2023, the Company conducted the fifth closing (the “Fifth OID Units Closing”) of a private placement (the “OID Units Private Placement”) of up to $10,000,000 for an aggregate of up to 100,000,000 units (“OID Units”), under a unit purchase agreement between the Company and each of nine investors (the “November 2023 OID Unit Purchase Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1413754/000149315223042333/0001493152-23-042333-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"each of nine investors"},{"label":"Value","value":"up to $10,000,000"},{"label":"Effective","value":"2023-11-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}